Nuclear and neuritic distribution of serine-129 phosphorylated α-synuclein in transgenic mice

[1]  L. Moran,et al.  Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease. , 2009, Parkinsonism & related disorders.

[2]  Daniel Sage,et al.  Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. , 2008, Human molecular genetics.

[3]  P. Lansbury,et al.  Phosphorylation at Ser-129 but Not the Phosphomimics S129E/D Inhibits the Fibrillation of α-Synuclein* , 2008, Journal of Biological Chemistry.

[4]  E. Waxman,et al.  Specificity and Regulation of Casein Kinase-Mediated Phosphorylation of &agr;-Synuclein , 2008, Journal of neuropathology and experimental neurology.

[5]  I. McKeith,et al.  Patterns and stages of α-synucleinopathy , 2008, Neurology.

[6]  R. Mandel,et al.  The phosphorylation state of Ser-129 in human α-synuclein determines neurodegeneration in a rat model of Parkinson disease , 2008, Proceedings of the National Academy of Sciences.

[7]  A. Siderowf,et al.  Cognitive Impairment in Parkinson’s Disease and Dementia with Lewy Bodies: A Spectrum of Disease , 2007, Neurosignals.

[8]  D. Mann,et al.  Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human α‐synuclein: Implication for α‐synucleinopathies , 2007 .

[9]  W. Spooren,et al.  Age-dependent cognitive decline and amygdala pathology in α-synuclein transgenic mice , 2007, Neurobiology of Aging.

[10]  T. Iwatsubo,et al.  Accumulation of phosphorylated α‐synuclein in dopaminergic neurons of transgenic mice that express human α‐synuclein , 2007 .

[11]  J. Parvin,et al.  Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. , 2006, Human molecular genetics.

[12]  R. Barbour,et al.  Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.

[13]  T. Iwatsubo,et al.  The Role of G-Protein-Coupled Receptor Kinase 5 in Pathogenesis of Sporadic Parkinson's Disease , 2006, The Journal of Neuroscience.

[14]  Masanori Kato,et al.  Investigation of Lewy pathology in the visual pathway of brains of dementia with Lewy bodies , 2006, Journal of the Neurological Sciences.

[15]  T. Dawson,et al.  Diagnosis and treatment of Parkinson disease: molecules to medicine. , 2006, The Journal of clinical investigation.

[16]  C. Ross,et al.  α-Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in SH-SY5Y Cells , 2005, The Journal of Neuroscience.

[17]  Masanori Kato,et al.  The nigro-striatal and nigro-amygdaloid pathways undergo different degeneration processes in brains of dementia with Lewy bodies , 2005, Neuroscience Letters.

[18]  M. Feany,et al.  α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease , 2005, Nature Neuroscience.

[19]  S. Resnick,et al.  Alpha-Synuclein Lesions in Normal Aging, Parkinson Disease, and Alzheimer Disease: Evidence from the Baltimore Longitudinal Study of Aging (BLSA) , 2005, Journal of neuropathology and experimental neurology.

[20]  T. Iwatsubo,et al.  Ubiquitination of α-Synuclein† , 2005 .

[21]  A Dürr,et al.  Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[22]  Philippe Amouyel,et al.  α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[23]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[24]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[25]  V. Uversky,et al.  Nuclear Localization of α-Synuclein and Its Interaction with Histones† , 2003 .

[26]  T. Iwatsubo,et al.  Accumulation of Phosphorylated α‐Synuclein in Aging Human Brain , 2003 .

[27]  Hideo Fujiwara,et al.  Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. , 2002, The Journal of clinical investigation.

[28]  G. Halliday,et al.  Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. , 2002, Brain : a journal of neurology.

[29]  Hideo Fujiwara,et al.  Hyperphosphorylation and insolubility of α‐synuclein in transgenic mouse oligodendrocytes , 2002 .

[30]  Toshiki Nakai,et al.  Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies , 2002, Journal of the Neurological Sciences.

[31]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[32]  J. Trojanowski,et al.  Selective Insolubility of α-Synuclein in Human Lewy Body Diseases Is Recapitulated in a Transgenic Mouse Model , 2001 .

[33]  J. Trojanowski,et al.  The fluorescent Congo red derivative, (trans, trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), labels diverse beta-pleated sheet structures in postmortem human neurodegenerative disease brains. , 2001, The American journal of pathology.

[34]  Glenda M. Halliday,et al.  Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr α‐synuclein mutation , 2001 .

[35]  Christian Haass,et al.  Subcellular Localization of Wild-Type and Parkinson's Disease-Associated Mutant α-Synuclein in Human and Transgenic Mouse Brain , 2000, The Journal of Neuroscience.

[36]  D. Dickson,et al.  Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease , 2000, Acta Neuropathologica.

[37]  J. Benovic,et al.  Synucleins Are a Novel Class of Substrates for G Protein-coupled Receptor Kinases* , 2000, The Journal of Biological Chemistry.

[38]  R. Hamilton,et al.  Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α‐Synuclein Immunohistochemistry , 2000, Brain pathology.

[39]  Joseph E LeDoux.  Emotion Circuits in the Brain , 2000 .

[40]  L. Meijer,et al.  Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein* , 2000, The Journal of Biological Chemistry.

[41]  J Q Trojanowski,et al.  Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. , 1998, The American journal of pathology.

[42]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[43]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[44]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[45]  R. Scheller,et al.  Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[46]  Joseph E LeDoux,et al.  Different projections of the central amygdaloid nucleus mediate autonomic and behavioral correlates of conditioned fear , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[47]  U Inserm,et al.  Causal relation between α synuclein gene duplication and familial Parkinson’s disease , 2005 .

[48]  Kurt Jellinger,et al.  Amygdala pathology in Parkinson's disease , 2004, Acta Neuropathologica.